ArticleBMC biotechnology2018
Efficient production of heat-stable antifungal factor through integrating statistical optimization with a two-stage temperature control strategy in Lysobacter enzymogenes OH11.
Article in BMC biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Hijacking competitor-derived signals: RcsB/C drivesApplied and environmental microbiology · 2026Article
- Investigation of the mechanisms involved in the biocontrol activities of natural products from a marine soil bacterium against rice blast.Pest management science · 2025Article
- Analysis of Co-localized Biosynthetic Gene Clusters Identifies a Membrane-Permeabilizing Natural Product.Journal of natural products · 2024Article
- Old role with new feature: T2SS ATPase as a cyclic-di-GMP receptor to regulate antibiotic production.Applied and environmental microbiology · 2024Article
- Iron ions regulate antifungal HSAF biosynthesis inMicrobiology spectrum · 2023Article
- A novel and high-efficient method for the preparation of heat-stable antifungal factor fromFrontiers in microbiology · 2023Article
- Evaluating the Mode of Antifungal Action of Heat-Stable Antifungal Factor (HSAF) inJournal of fungi (Basel, Switzerland) · 2022Article
- The predatory soil bacterium Lysobacter reprograms quorum sensing system to regulate antifungal antibiotic production in a cyclic-di-GMP-independent manner.Communications biology · 2021Article
- Separation of Heat-Stable Antifungal Factor FromFrontiers in microbiology · 2021Article
- Enhanced AmB Production inFrontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeat-stable antifungal factor (HSAF) is a newly identified broad-spectrum antifungal antibiotic from the biocontrol agent Lysobacter enzymogenes and is regarded as a potential biological pesticide, due to its novel mode of action. However, the production level of HSAF is quite low, and little research has reported on the fermentation process involved, representing huge obstacles for large-scale industrial production.
resultsMedium capacity, culture temperature, and fermentation time were identified as the most significant factors affecting the production of HSAF and employed for further optimization through statistical methods. Based on the analysis of kinetic parameters at different temperatures, a novel two-stage temperature control strategy was developed to improve HSAF production, in which the temperature was increased to 32 °C during the first 12 h and then switched to 26 °C until the end of fermentation. Using this strategy, the maximum HSAF production reached 440.26 ± 16.14 mg L
conclusionsThis study provides a simple and efficient method for producing HSAF that could be feasibly applied to the industrial-scale production of HSAF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.